Adcock Ingram

Adcock Ingram FY HEPS came in 9% higher to 616.6c (vs BB est. of 564.9c) | Revenue +6% to R9.6bn: OTC & Hospital rev. both +8%, while the larger Consumer & Prescription segments (by rev.) rose 3% & 4%, respectively | Operating profit -6% to R1.06bn | NAV -4% to 3688c | Final divi +20% to 150c | AIP is on a ~10.6% PE
Click here to read the SENS